Topic:
Chutes and Ladders
Latest Headlines
Latest Headlines
Eli Lilly appoints Melissa Barnes as chief ethics and compliance officer
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Theratechnologies once again tries to slash its way to breakeven point
Ten months ago, Montreal-based Theratechnologies ($THER) cut its staff, shelved a mid-stage development program and slashed costs, vowing to get on track to profitability in 2013. And that was the second round of layoffs it engineered in 2011.
Aveo slashes workforce, circles wagons around troubled kidney cancer drug
The company's CEO says that 45 staffers are being pink slipped--17% of the workforce--while another 30 open positions will not be filled. The move should save some $100 million over three years.
GSK hunts for new chairman as Gent preps for departure
GlaxoSmithKline chairman Christopher Gent is preparing to exit stage left. But he's not packing his bags just yet.
Pfizer reps to bear brunt of Canadian layoffs
More job cuts at Pfizer ($PFE). The world's biggest drugmaker is shedding 300 from its Canadian workforce, or about 11% of its employees in the country. Hardest hit will be sales and marketing, particularly in primary care.
Shire's Angus Russell will retire from CEO post in 2013
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Shire chief prepares to hand over reins to hand-picked successor
Shire CEO Angus Russell's 13-year stint at the helm has provided a classic case study on how to efficiently build a biotech company.
Teva, HGS beef up layoff plans in U.S.
More jobs are trickling away in the drug business. Two companies slated new rounds of layoffs today, both of them spurred by common pharma-industry events.
Abbott adds 550 to layoffs toll as split-up nears
For the third quarter, Abbott Laboratories ($ABT) raised profits on lower sales. Margins saved the day. Now, the company is cutting more jobs--a total of 550 from several business units--a move designed to shave costs as it prepares to split into two separate operations.
The top 10 pharma layoffs of 2012
By the beginning of 2012, the pharma industry had endured one of the biggest shakeouts in the industry's history. Tens of thousands of jobs had been eliminated and most employees had good reason to fear they would be next. Just after the New Year, PharmaIQ reported that a survey revealed that 44% of the people they contacted were afraid of losing their jobs. Click here to read the full report >>
